ClinicalTrials.gg
CompletedNCT00482729Updated Jun 9, 2017Results posted

MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)

A Phase 3 interventional study of sitagliptin phosphate (+) metformin hydrochloride and metformin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-06-09.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,246
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
5th of 197
1,246 · median 102
Started
2007
with 16 others
Phase 3
74 of 198
none open now
Registered
28th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 74 in phase 3, and was the 28th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and safety of an investigational treatment for type 2 diabetes mellitus.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has type 2 diabetes mellitus
  • Patient is greater than or equal to 18 and less than or equal to 78 years of age on the day of signing the consent
  • Patient has Hb1Ac greater than or equal to 7.5% and is appropriate for oral therapy
  • Patient has not been on any antihyperglycemic agent (AHA) in the last 4 months
  • Patient is a male, or a female who is unlikely to conceive

Exclusion criteria

Exclusion Criteria:

  • Patient has type 1 diabetes mellitus or history of ketoacidosis
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,246 participants (actual)

Study arms

  • Experimental
    1

    Arm 1: drug

    Drug: sitagliptin phosphate (+) metformin hydrochloride

  • Active comparator
    2

    Arm 2: active comparator

    Drug: metformin

Interventions

  • Drugsitagliptin phosphate (+) metformin hydrochloride

    Drug pages: Sitagliptin · Metformin

    sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.

    Also known as: MK0431A, Janumet™

  • metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (A1C) at Week 18

    A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.

    Time frame: Baseline and Week 18

Secondary outcomes

  1. Number of Patients With A1C < 7.0% at Week 18

    Time frame: Week 18

  2. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18

    FPG is measured as mg/dL. Thus, this change from baseline reflects the Week 18 FPG mg/dL minus the Week 0 FPG mg/dL.

    Time frame: Baseline and Week 18

Other outcomes

  1. Change From Baseline in A1C at Week 44

    A1C is measured as percent. Thus, this change from baseline reflects the Week 44 A1C percent minus the Week 0 A1C percent.

    Time frame: Baseline and Week 44

  2. Number of Patients With A1C < 7.0% at Week 44

    Time frame: Week 44

07

Results

Posted Mar 15, 2010
Limitations and caveats
Site 079011301 was non-compliant with Good Clinical Practice (GCP). Data from the 4 patients at this site are included in the Participant Flow summary, but are excluded from all other summaries and analyses.

Participant flow

First Patient In: 26-Jun-2007; Last Patient Last Visit for end of study: 28-Apr-2009; Two-hundred four medical clinics in the United States (US) and 5 in Puerto Rico.

Participant flow — Overall Study
MilestoneSita/Met FDCMetformin
Started626624
Completed phase a484482
Completed phase b409406
Completed409406
Not completed217218
Withdrew: Adverse event2933
Withdrew: Creatinine/creatinine clearance criteria02
Withdrew: Hyperglycemia criteria75
Withdrew: Lack of efficacy416
Withdrew: Lost to follow-up8666
Withdrew: Physician decision107
Withdrew: Pregnancy42
Withdrew: Protocol violation1018
Withdrew: Withdrawal by subject6769

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (A1C) at Week 18

A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · Percent
Change From Baseline in Hemoglobin A1c (A1C) at Week 18
PercentSita/Met FDCMetformin
Change From Baseline in Hemoglobin A1c (A1C) at Week 18-2.37 (-2.49 to -2.24)-1.76 (-1.88 to -1.64)
Statistical analysis
  • Sita/Met FDC vs Metformin · ANCOVA · p = <0.001 · Mean difference (net): -0.60 · 95% CI -0.78 to -0.43Model terms: treatment, baseline A1C
SecondaryNumber of Patients With A1C < 7.0% at Week 18
Time frame:
Week 18
Reported as:
Number · Participants
Number of Patients With A1C < 7.0% at Week 18
ParticipantsSita/Met FDCMetformin
Patients with A1C <7.0% at Week 18275193
Patients with A1C ≥7.0% at Week 18284371
Statistical analysis
  • Sita/Met FDC vs Metformin · ANCOVA · p = <0.001 (Based on a test of the odds ratio = 1, comparing the odds of having A1C \<7.0% at Week 18 in the Sita/Met FDC group vs. the Metformin group.) · Odds ratio (or): 2.07 · 95% CI 1.60 to 2.69This parameter estimate and 95% confidence interval correspond to the odds of having A1C \<7.0% at Week 18 in the Sita/Met FDC group vs. the Metformin group.
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 18

FPG is measured as mg/dL. Thus, this change from baseline reflects the Week 18 FPG mg/dL minus the Week 0 FPG mg/dL.

Time frame:
Baseline and Week 18
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18
mg/dLSita/Met FDCMetformin
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18-69.4 (-74.1 to -64.6)-53.7 (-58.4 to -48.9)
Statistical analysis
  • Sita/Met FDC vs Metformin · ANCOVA · p = <0.001 · Mean difference (net): -15.7 · 95% CI -22.4 to -9.0Model terms: treatment, baseline A1C
Other pre-specifiedChange From Baseline in A1C at Week 44

A1C is measured as percent. Thus, this change from baseline reflects the Week 44 A1C percent minus the Week 0 A1C percent.

Time frame:
Baseline and Week 44
Reported as:
Least squares mean · Percent
Change From Baseline in A1C at Week 44
PercentSita/Met FDCMetformin
Change From Baseline in A1C at Week 44-2.25 (-2.38 to -2.12)-1.77 (-1.89 to -1.64)
Statistical analysis
  • Sita/Met FDC vs Metformin · Mean difference (net): -0.48 · 95% CI -0.67 to -0.30This is a difference in least squares means, based on an ANCOVA model with terms for treatment and baseline (i.e., Week 0) A1C.
Other pre-specifiedNumber of Patients With A1C < 7.0% at Week 44
Time frame:
Week 44
Reported as:
Number · Participants
Number of Patients With A1C < 7.0% at Week 44
ParticipantsSita/Met FDCMetformin
Patients with A1C <7.0% at Week 44258173
Patients with A1C ≥7.0% at Week 44302396
Statistical analysis
  • Sita/Met FDC vs Metformin · Odds ratio (or): 2.11 · 95% CI 1.63 to 2.73This parameter estimate and 95% confidence interval correspond to the odds of having A1C \<7.0% at Week 44 in the Sita/Met FDC group vs. the Metformin group, based on a logistic regression model with terms for treatment and baseline (i.e., Week 0) A1C

Adverse events

Collected over Week 0 through Week 44. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sita/Met FDC—28/625 (4.5%)173/625 (27.7%)
Metformin—38/621 (6.1%)185/621 (29.8%)
Most frequent serious events
Showing 10 of 78
Most frequent serious events
EventSita/Met FDCMetformin
Any Cardiac DisordersCardiac disorders5/6256/621
Any Infections and InfestationsInfections and infestations6/6256/621
Any Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasms benign, malignant and unspecified (incl cysts and polyps)3/6255/621
Any Nervous System DisordersNervous system disorders1/6255/621
Any Vascular DisordersVascular disorders2/6254/621
Coronary artery diseaseCardiac disorders1/6253/621
Any General Disorders and Administration site ConditionsGeneral disorders1/6253/621
Any Psychiatric DisordersPsychiatric disorders2/6253/621
Any Respiratory, Thoracic and Mediastinal DisordersRespiratory, thoracic and mediastinal disorders3/6251/621
Any Gastrointestinal DisordersGastrointestinal disorders2/6252/621
Most frequent other events
Most frequent other events
EventSita/Met FDCMetformin
Any Gastrointestinal DisordersGastrointestinal disorders107/625136/621
DiarrhoeaGastrointestinal disorders86/625112/621
Any Infections and infestationsInfections and infestations62/62557/621
NauseaGastrointestinal disorders37/62544/621
Any Nervous system disordersNervous system disorders35/62523/621
HeadacheNervous system disorders35/62523/621
NasopharyngitisInfections and infestations33/62526/621
Upper respiratory tract infectionInfections and infestations30/62531/621

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sita/Met FDCMetforminTotal
Mean49.4 ± 10.550.0 ± 10.549.7 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Sita/Met FDCMetforminTotal
Female272266538
Male353355708
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sita/Met FDCMetforminTotal
Asian172441
Black8288170
White508489997
Other182038
Hemoglobin A1c (A1C)
Hemoglobin A1c (A1C)(Percent)Sita/Met FDCMetforminTotal
Mean9.91 ± 1.839.83 ± 1.779.87 ± 1.80
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Reasner C, Olansky L, Seck TL, Williams-Herman DE, Chen M, Terranella L, Johnson-Levonas AO, Kaufman KD, Goldstein BJ. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011 Jul;13(7):644-52. doi: 10.1111/j.1463-1326.2011.01390.x. PubMed 21410627 ↗
  • Olansky L, Reasner C, Seck TL, Williams-Herman DE, Chen M, Terranella L, Mehta A, Kaufman KD, Goldstein BJ. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. Diabetes Obes Metab. 2011 Sep;13(9):841-9. doi: 10.1111/j.1463-1326.2011.01416.x. PubMed 21535346 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2007 to primary completion in Nov 2008, 16 months.

Results were first posted in Mar 2010, 1 year 4 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2007
First posted
Jun 5, 2007
StartActual
Jun 19, 2007
Primary completionActual
Nov 3, 2008
CompletionActual
Apr 27, 2009
Results first posted
Mar 15, 2010
Last update
Jun 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00482729
Responsible party
Sponsor
First posted
Jun 5, 2007
Start date
Jun 19, 2007
Primary completion
Nov 3, 2008
Completion
Apr 27, 2009
Results posted
Mar 15, 2010
Last update
Jun 9, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitagliptin · Metformin

Start the discussion